Clinicians now have a new way to fight shingles, and the vaccine has been listed as the preferred choice over its predecessor by at least one federal agency.
The for adults aged 50 and older in October 2017, and x, which was the only shingles vaccine available until now. FDA's approval and ACIP's recommendation were based on a Phase III clinical trial program evaluating the vaccine's safety and efficacy in a cohort of more than 38,000 individuals. The trials showed 90% efficacy across all age groups, according to the vaccine's manufacturer GSK.
Shingles is caused by the reactivation of the varicella zoster virus (VZV), the same virus that causes chickenpox. Most adults have the virus in their system, but it lies dormant until reactivated--usually as an individual ages and their immune system declines. The reactivated virus presents with a painful, itchy rash that can last for weeks with pain continuing for months in more extreme cases.
Len Friedland, MD, vice president of Scientific Affairs and Public Health at GSK, said there are more than 1 million new cases of shingles every year, and all adults have a 1 in 3 chance of developing the infection. In individuals aged 85 and older, that risk increases to 1 in 2, he said.
"Shingles can be really impactful and change people's lives," Friedland told Medical Economics. “Its clinical presentation is a very severe type of pain that can really stop people in their tracks. People refer to the pain as the type of pain they experience when they deliver a child or have a kidney stone.”
In addition to the pain of shingles infection, patients can experience acute complications including postherpetic neuralgia (PHN), a form of chronic nerve pain and the most common complication associated with shingles.
was approved by the FDA in 2006 and has been the only vaccine for shingles until now. It is a live vaccine and licensed for patients 60 and older, according to the FDA.
Shingrix is a non-live vaccine using recombinant antigens and adjuvants to enhance immune response. Friedland said testing of the vaccine showed 90% efficacy in preventing the development of shingles over a four-year period.
“The results have proven that this approach has generated a high level of protection for people regardless of age,” Friedland said.